Portfolio
1 totalCo-Investors
6Latest Pulse
- Aug 28, 2026Owner Raises $240M at $2.3B to Run Local BusinessesOwner, the AI platform that runs websites, ordering, marketing and phone support for restaurants, raised $240 million led by Growth Equity at Goldman Sachs Alternatives at a $2.3 billion valuation.→
- Aug 11, 2026Vaderis Raises $152M Series B for Rare Disease TrialVaderis Therapeutics closed an oversubscribed $152.5 million Series B co-led by Goldman Sachs Alternatives and TCGX to fund a global Phase 3 trial of its drug for a rare blood vessel disorder.→
- Jul 29, 2026Goldman-Backed Attovia Seeks $212.5M in Biotech IPOAttovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.→
- Jul 13, 2026Helsing Raises $1.8B, Europe's Biggest Defense RoundMunich-based Helsing closed a $1.8 billion Series E at an $18 billion valuation, Europe's biggest-ever defense-tech round, with Goldman Sachs Alternatives, CPPIB and JPMorgan joining as new investors amid oversubscribed demand.→
- Jun 24, 2026Taktile Raises $110M Series C Led by Goldman Sachs for AI Decisioning in FinanceTaktile raised a $110 million Series C led by Goldman Sachs Alternatives to scale its AI decisioning platform, which lets banks and insurers automate underwriting, claims, fraud detection and anti-money-laundering workflows with human oversight. The round is a vote of confidence that regulated financial institutions will pay for AI that makes high-stakes decisions auditable rather than just faster.→